Effect of early versus deferred antiretroviral therapy for HIV on survival

Authors :: Kitahata, Mari M.
Gange, Stephen J.
Abraham, Alison G.
Merriman, Barry
Saag, Michael S.
Justice, Amy C.
Hogg, Robert S.
Deeks, Steven G.
Eron, Joseph J.
Brooks, John T.
Rourke, Sean B.
Gill, M. John
Bosch, Ronald J.
Martin, Jeffrety N.
Klein, Marina B.
Jacobson, Lisa P.
Rodriguez, Benigno
Sterling, Timothy R.
Kirk, Gregory D.
Napravnik, Sonia
Rachlis, Anita R.
Calzavara, Liviana M.
Horberg, Michael A.
Silverberg, Michael J.
Gebo, Kelly A.
Goedert, James J.
Benson, Constance A.
Collier, Ann C.
Van Rompaey ,Stephen E.
Crane, Heidi M.
McKaig, Rosemary G.
Lau, Bryan
Freeman, Aimee M.
Moore, Richard D.
Source :: The New England Journal of Medicine. April 30, 2009, Vol. 360 Issue 18, p1815, 12 p.
Publication Year :: 2009
Abstract: Several analyses are conducted to determine the appropriate time for starting the antiretroviral therapy for the patients with human immunodeficiency virus (HIV) infection. An early initiation of the therapy is shown to highly increase the chances of survival of the patients, as compared to the deferred beginning.

Subjects :: HIV patients -- Care and treatment
Antiviral agents -- Health aspects
HIV infection -- Risk factors
HIV infection -- Drug therapy

Tools